On the KUSp of Neuroprotective Medicine
Novel compounds prevent disease progression in mouse models of glaucoma
Are we finally on the cusp of treating neurodegenerative ocular disease by neuroprotection? Currently, IOP is the only modifiable risk factor for glaucoma, but today’s treatments – despite their successes in reducing IOP – are not always effective, as many patients continue to experience gradual loss in vision (albeit at a less dramatic pace) with treatment. Whilst efforts in the glaucoma field have been focusing on neuroprotective treatments, so far these have been to little avail (1).
Enter Hanako Ikeda and her team at Kyoto University. Two years ago, they published research showing that their novel neuroprotectant compounds – termed Kyoto University Substances (KUSs) – prevented photoreceptor cell death and preserved visual function in a mouse model of retinitis pigmentosa (2). Now they have shown that KUSs can prevent glaucoma progression and loss of visual function in three different mouse models, through suppressing the loss of retinal ganglion cells (RGCs) and nerve fibers (3). But what exactly are KUSs and how do they work?
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.